Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGCG for cardiac AL amyloidosis
NCT01511263Phase 2Terminated
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Jan 2012
- Primary completion
- Jul 2016
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of epigallocatechin gallate in amyloid light chain amyloidosis, sponsored by IRCCS San Matteo Foundation. Primary endpoint: Cardiac response rate at 6 months. Started Jan 2012; status: terminated.
02
Drugs
epigallocatechin gallate
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT01511263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01511263.